$620,000 of ARDELYX INC. lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act"
You can find more data on corporate lobbying on Quiver Quantitative.
ARDX Insider Trading Activity
ARDX insiders have traded $ARDX stock on the open market 25 times in the past 6 months. Of those trades, 4 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $ARDX stock by insiders over the last 6 months:
- DAVID M MOTT has made 4 purchases buying 705,897 shares for an estimated $3,374,588 and 0 sales.
- MICHAEL RAAB (President & CEO) has made 0 purchases and 10 sales selling 299,353 shares for an estimated $1,568,749.
- DAVID P. ROSENBAUM (Chief Development Officer) has made 0 purchases and 4 sales selling 61,527 shares for an estimated $361,860.
- LAURA A WILLIAMS (Chief Medical Officer) has made 0 purchases and 2 sales selling 12,307 shares for an estimated $63,099.
- ELIZABETH A GRAMMER (See Remarks) has made 0 purchases and 2 sales selling 11,337 shares for an estimated $57,910.
- JUSTIN A RENZ (Chief Financial Officer) has made 0 purchases and 2 sales selling 10,431 shares for an estimated $54,295.
- ROBERT BLANKS (See Remarks) sold 4,941 shares for an estimated $23,689
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARDX Hedge Fund Activity
We have seen 116 institutional investors add shares of ARDX stock to their portfolio, and 94 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 2,858,061 shares (+13.3%) to their portfolio in Q4 2024, for an estimated $14,490,369
- TWO SEAS CAPITAL LP added 1,855,337 shares (+inf%) to their portfolio in Q4 2024, for an estimated $9,406,558
- EVENTIDE ASSET MANAGEMENT, LLC removed 1,812,285 shares (-24.4%) from their portfolio in Q4 2024, for an estimated $9,188,284
- ROCK SPRINGS CAPITAL MANAGEMENT LP added 1,463,629 shares (+inf%) to their portfolio in Q4 2024, for an estimated $7,420,599
- D. E. SHAW & CO., INC. added 1,453,369 shares (+9499.8%) to their portfolio in Q4 2024, for an estimated $7,368,580
- MACQUARIE GROUP LTD added 1,398,144 shares (+15.6%) to their portfolio in Q4 2024, for an estimated $7,088,590
- RUBRIC CAPITAL MANAGEMENT LP removed 1,353,706 shares (-44.2%) from their portfolio in Q4 2024, for an estimated $6,863,289
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARDX Analyst Ratings
Wall Street analysts have issued reports on $ARDX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Outperform" rating on 03/07/2025
- BTIG issued a "Buy" rating on 03/04/2025
- Jefferies issued a "Buy" rating on 01/02/2025
To track analyst ratings and price targets for ARDX, check out Quiver Quantitative's $ARDX forecast page.
ARDX Price Targets
Multiple analysts have issued price targets for $ARDX recently. We have seen 2 analysts offer price targets for $ARDX in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- An analyst from BTIG set a target price of $14.0 on 03/04/2025
- Dennis Ding from Jefferies set a target price of $8.0 on 01/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
